Ironwood Pharmaceuticals | IRWD - Selling And Administration Expenses


Ironwood Pharmaceuticals reported $33.33M in Selling and Administration Expenses for its fiscal quarter ending in December of 2024.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 124.9M 1.24M Sep/2025
Agios Pharmaceuticals USD 42.97M 1.7M Dec/2025
Akebia Therapeutics USD 25.74M 1.93M Mar/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Amarin USD 17.94M 17.86M Sep/2025
Ardelyx USD 83.61M 378K Sep/2025
Astellas Pharma JPY 221.78B 14.94B Dec/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
Charles River Laboratories USD 196.14M 18.55M Dec/2025
Coherus Biosciences USD 26.02M 8.57M Mar/2025
Emergent BioSolutions USD 182.8M 82.3M Jun/2023
Esperion Therapeutics USD 39.98M 4.21M Sep/2024
Exact Sciences USD 491.64M 35.94M Sep/2025
Halozyme Therapeutics USD 64.64M 27.11M Dec/2025
Incyte USD 390.41M 61.33M Dec/2025
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
Karyopharm Therapeutics USD 27.19M 442K Dec/2024
Lexicon Pharmaceuticals USD 39.19M 7.13M Jun/2024
MacroGenics USD 9.9M 600K Sep/2025
Moderna USD 308M 40M Dec/2025
Myriad Genetics USD 129M 1.3M Sep/2025
Pacira USD 91.8M 14.6M Sep/2025
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Sarepta Therapeutics USD 77.11M 7.22M Sep/2025
Takeda JPY 282.78B 29.23B Dec/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024